| Q47868183 | -643C > T RANKL gene polymorphism is associated with osteoporosis in Tunisian postmenopausal women |
| Q46008001 | 1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. |
| Q34339766 | 2‐Methoxystypandrone represses RANKL‐mediated osteoclastogenesis by down‐regulating formation of TRAF6–TAK1 signalling complexes |
| Q35683586 | 6. Cathepsin K inhibitors: their potential as anti-osteoporosis agents |
| Q80243457 | A C >T polymorphism located at position -1 of the Kozak sequence of CD40 gene is associated with low bone mass in Spanish postmenopausal women |
| Q64107402 | A Novel Small Molecule Which Increases Osteoprotegerin Expression and Protects Against Ovariectomy-Related Bone Loss in Rats |
| Q57184035 | A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF |
| Q42007592 | A T Cell View of the Bone Marrow |
| Q34567407 | A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss |
| Q36869250 | A genome-wide association study of myasthenia gravis |
| Q47326665 | A new histomorphometric method to assess growth plate chondrodysplasia and its application to the toothless (tl, Csf1(null)) osteopetrotic rat. |
| Q24538937 | A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO) |
| Q46743257 | A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response |
| Q33459357 | A novel osteoclast precursor cell line, 4B12, recapitulates the features of primary osteoclast differentiation and function: enhanced transfection efficiency before and after differentiation |
| Q28235394 | A novel pathway involving progesterone receptor, 12/15-lipoxygenase-derived eicosanoids, and peroxisome proliferator-activated receptor gamma regulates implantation in mice |
| Q24292059 | A novel zinc finger protein that inhibits osteoclastogenesis and the function of tumor necrosis factor receptor-associated factor 6 |
| Q51261742 | A tumor necrosis factor-alpha antagonist inhibits inflammatory bone resorption induced by Porphyromonas gingivalis infection in mice. |
| Q53364532 | A unique domain in RANK is required for Gab2 and PLCgamma2 binding to establish osteoclastogenic signals. |
| Q37706111 | Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer |
| Q34561579 | Ablation of Tak1 in osteoclast progenitor leads to defects in skeletal growth and bone remodeling in mice |
| Q36538837 | Abnormal lymphoid organ development in immunodeficient mutant mice. |
| Q34356123 | Activation of EPAC1/2 is essential for osteoclast formation by modulating NFκB nuclear translocation and actin cytoskeleton rearrangements |
| Q40838540 | Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor |
| Q33783389 | Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice |
| Q35951939 | Adenosine A(2A) receptor ligation inhibits osteoclast formation. |
| Q34036039 | Adenosine and bone metabolism |
| Q33649260 | Afatinib ameliorates osteoclast differentiation and function through downregulation of RANK signaling pathways. |
| Q37150524 | Alopecia areata after denosumab treatment for osteoporosis |
| Q35569854 | An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction |
| Q24806847 | Anti-TNF-alpha therapy as a clinical intervention for periprosthetic osteolysis |
| Q85746797 | Anti-interleukin-6 receptor antibody prevents systemic bone mass loss via reducing the number of osteoclast precursors in bone marrow in a collagen-induced arthritis model |
| Q57904725 | Antibodies to receptor activator of nuclear factor-κ B ligand (RANKL) |
| Q34774678 | Antibody-mediated "universal" osteoclast targeting platform using calcitonin as a model drug. |
| Q37030353 | Antigen sampling by intestinal M cells is the principal pathway initiating mucosal IgA production to commensal enteric bacteria |
| Q90229560 | Applying a weight of evidence approach to the evaluation of developmental toxicity of biopharmaceuticals |
| Q34107428 | Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. |
| Q35629551 | Aseptic loosening |
| Q39367844 | Association between RANK, RANKL and OPG polymorphisms with ACPA and erosions in rheumatoid arthritis: results from a meta-analysis involving three French cohorts. |
| Q64071625 | Association of Genetic Variants of , , and with Ankylosing Spondylitis Clinical Features in Taiwanese |
| Q40633472 | Association of sustained ERK activity with integrin beta3 induction during receptor activator of nuclear factor kappaB ligand (RANKL)-directed osteoclast differentiation |
| Q35750515 | Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis |
| Q35222008 | B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease |
| Q36324944 | B cells and osteoblast and osteoclast development |
| Q37190057 | B1a cells play a pathogenic role in the development of autoimmune arthritis. |
| Q91802599 | Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade |
| Q28265584 | Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab |
| Q47104578 | Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway |
| Q47194100 | Beyond Antibodies: B Cells and the OPG/RANK-RANKL Pathway in Health, Non-HIV Disease and HIV-Induced Bone Loss |
| Q24701763 | Bindarit, an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss induced by chikungunya virus infection |
| Q34366449 | Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond |
| Q35145622 | Biology of the TRANCE axis |
| Q51873934 | Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy. |
| Q35878832 | Bone Is a Major Target of PTH/PTHrP Receptor Signaling in Regulation of Fetal Blood Calcium Homeostasis. |
| Q33727278 | Bone Metastases: An Overview |
| Q36737006 | Bone disease in multiple myeloma |
| Q82748766 | Bone diseases: Interferon regulatory factor-8 suppresses osteoclastogenesis |
| Q24805142 | Bone loss. Factors that regulate osteoclast differentiation: an update |
| Q52884931 | Bone marrow stromal cells induced activation of nuclear factor κB signaling protects non-Hodgkin's B lymphoma cells from apoptosis. |
| Q94673370 | Bone-Targeting AAV-Mediated Gene Silencing in Osteoclasts for Osteoporosis Therapy |
| Q35780792 | Bone-targeted agents in the treatment of lung cancer. |
| Q37728708 | Bovine lactoferrin improves bone mass and microstructure in ovariectomized rats via OPG/RANKL/RANK pathway |
| Q37362838 | Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases |
| Q34939979 | Breast cancer at bone metastatic sites: recent discoveries and treatment targets. |
| Q35894360 | CHMP5 controls bone turnover rates by dampening NF-κB activity in osteoclasts |
| Q42586718 | CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany |
| Q43018265 | Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section |
| Q36884628 | Cancer to bone: a fatal attraction |
| Q36480304 | Canonical Notch activation in osteocytes causes osteopetrosis |
| Q92422137 | Cartilage and Bone Destruction in Arthritis: Pathogenesis and Treatment Strategy: A Literature Review |
| Q34472121 | Cell adhesion signaling regulates RANK expression in osteoclast precursors |
| Q38126407 | Cells of the immune system orchestrate changes in bone cell function |
| Q37783746 | Cellular and Molecular Requirements in Lymph Node and Peyer's Patch Development |
| Q64057496 | Changes in bone metabolic profile associated with pregnancy or lactation |
| Q38457496 | Checkpoints that control B cell development |
| Q34167947 | Chemokines in lymphopoiesis and lymphoid organ development |
| Q47796415 | Cherubism Mice Also Deficient in c-Fos Exhibit Inflammatory Bone Destruction Executed by Macrophages That Express MMP14 Despite the Absence of TRAP+ Osteoclasts |
| Q30540259 | Chinese Herbal Formula Huo-Luo-Xiao-Ling Dan Protects against Bone Damage in Adjuvant Arthritis by Modulating the Mediators of Bone Remodeling |
| Q89491066 | Chinese Society of Allergy and Chinese Society of Otorhinolaryngology-Head and Neck Surgery Guideline for Chronic Rhinosinusitis |
| Q36017881 | Chondrocytes-Specific Expression of Osteoprotegerin Modulates Osteoclast Formation in Metaphyseal Bone |
| Q41658178 | Chromosome 18q deletion syndrome with autoimmune diabetes mellitus: putative genomic loci for autoimmunity and immunodeficiency |
| Q37894283 | Citrullination of autoantigens: upstream of TNFα in the pathogenesis of rheumatoid arthritis. |
| Q51361368 | Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases. |
| Q35901092 | Clinical development of anti-RANKL therapy |
| Q35184335 | Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders |
| Q82306970 | Clinical use of denosumab for the treatment for postmenopausal osteoporosis |
| Q52859590 | Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. |
| Q97524968 | Comparative transcriptomic analysis identifies distinct molecular signatures and regulatory networks of chondroclasts and osteoclasts |
| Q33849260 | Complementary interplay between matrix metalloproteinase-9, vascular endothelial growth factor and osteoclast function drives endochondral bone formation |
| Q35084291 | Concerted action of the chemokine and lymphotoxin system in secondary lymphoid-organ development |
| Q33912625 | Contradictory Role of CD97 in Basal and Tumor Necrosis Factor-Induced Osteoclastogenesis In Vivo |
| Q27635130 | Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity |
| Q47131626 | Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation |
| Q44496075 | Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc1 and enhancing cell apoptosis |
| Q35064876 | Defective lymphoid organogenesis underlies the immune deficiency caused by a heterozygous S32I mutation in IκBα. |
| Q35624565 | Deficiency of foxp3 regulatory T cells exacerbates autoimmune arthritis by altering the synovial proportions of CD4 T cells and dendritic cells |
| Q30534461 | Deletion of CD74, a putative MIF receptor, in mice enhances osteoclastogenesis and decreases bone mass |
| Q38832148 | Deletion of a Distal RANKL Gene Enhancer Delays Progression of Atherosclerotic Plaque Calcification in Hypercholesterolemic Mice. |
| Q37810423 | Denosumab for the management of postmenopausal osteoporosis |
| Q38986160 | Denosumab for the treatment of giant cell tumor of the bone. |
| Q37967111 | Denosumab for the treatment of osteoporosis and cancer-related conditions |
| Q36056922 | Denosumab in postmenopausal osteoporosis: what the clinician needs to know |
| Q37679921 | Denosumab--an emerging treatment for postmenopausal osteoporosis |
| Q43267044 | Denosumab: a promising drug for the prevention and treatment of osteoporosis |
| Q37307805 | Denosumab: an investigational drug for the management of postmenopausal osteoporosis |
| Q34545263 | Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis. |
| Q34764895 | Development of secondary lymphoid organs |
| Q93012733 | Developmental origin, functional maintenance and genetic rescue of osteoclasts |
| Q78651212 | Different cytokines induce surface lymphotoxin-alphabeta on IL-7 receptor-alpha cells that differentially engender lymph nodes and Peyer's patches |
| Q39303782 | Differential RET signaling pathways drive development of the enteric lymphoid and nervous systems |
| Q37342578 | Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT. |
| Q53099931 | Differential expression of chemokines, chemokine receptors and proteinases by foreign body giant cells (FBGCs) and osteoclasts. |
| Q27682535 | Discovery and characterization of olokizumab |
| Q28295303 | Disorders of Bone Remodeling |
| Q90265843 | Disruption of the preB Cell Receptor Complex Leads to Decreased Bone Mass |
| Q37767159 | Do RANKL inhibitors (denosumab) affect inflammation and immunity? |
| Q91921619 | Does TNF Promote or Restrain Osteoclastogenesis and Inflammatory Bone Resorption? |
| Q35537992 | Effect of amorphous silica nanoparticles on in vitro RANKL-induced osteoclast differentiation in murine macrophages. |
| Q43648798 | Effect of heat stress on the expression levels of receptor activator of NF-κB ligand and osteoprotegerin in human periodontal ligament cells |
| Q36375272 | Effect of hypoxia on the expression of RANKL/OPG in human periodontal ligament cells in vitro |
| Q42829247 | Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-kappaB and receptor activator of nuclear factor kappaB (RANK)/RANK ligand signaling? |
| Q36383174 | Effect of radiation on the expression of osteoclast marker genes in RAW264.7 cells |
| Q42706677 | Effects of Brucine on the OPG/RANKL/RANK Signaling Pathway in MDA-MB-231 and MC3T3-E1 Cell Coculture System. |
| Q40077779 | Effects of IL-10 and glucose on expression of OPG and RANKL in human periodontal ligament fibroblasts |
| Q37441693 | Effects of RANKL-Targeted Therapy in Immunity and Cancer |
| Q34162783 | Effects of antiresorptive agents on osteomyelitis: novel insights into the pathogenesis of osteonecrosis of the jaw. |
| Q59419714 | Effects of denosumab on peripheral lymphocyte subpopulations |
| Q47846447 | Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing |
| Q45884566 | Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis |
| Q21131222 | Emerging Functions of RANKL in Lymphoid Tissues |
| Q38857186 | Enterococcus faecalis promotes osteoclastogenesis and semaphorin 4D expression |
| Q35901078 | Erosive arthritis |
| Q42015911 | Essential role of nuclear factor (NF)-kappaB-inducing kinase and inhibitor of kappaB (IkappaB) kinase alpha in NF-kappaB activation through lymphotoxin beta receptor, but not through tumor necrosis factor receptor I |
| Q24300916 | Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1 |
| Q51746101 | Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis. |
| Q35133898 | Evaluation of rs3102735 and rs2073617 Osteoprotegerin Gene Polymorphisms and the Risk of Childhood Acute lymphoblastic Leukemia in Zahedan Southeast Iran |
| Q38699879 | Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy |
| Q33583910 | Exploring codon optimization and response surface methodology to express biologically active transmembrane RANKL in E. coli |
| Q44480300 | Expression of RANK is dependent upon differentiation into the macrophage/osteoclast lineage: induction by 1alpha,25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line, HL60. |
| Q28575953 | Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation |
| Q34014506 | FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner |
| Q45265379 | Familial expansive osteolysis otological and dental manifestations of genetic origin |
| Q90412365 | Ferryl Hemoglobin Inhibits Osteoclastic Differentiation of Macrophages in Hemorrhaged Atherosclerotic Plaques |
| Q74810016 | Fetal anasarca (Hydrops foetalis) associated with lymphoid tissue agenesis possibly due to an autosomal recessive gene defect in sheep |
| Q92405045 | Finding a Toll on the Route: The Fate of Osteoclast Progenitors After Toll-Like Receptor Activation |
| Q44375296 | Foreign body giant cells and osteoclasts are TRAP positive, have podosome-belts and both require OC-STAMP for cell fusion. |
| Q57675158 | Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation |
| Q35659426 | From the ranks of mammary progesterone mediators, RANKL takes the spotlight |
| Q36700779 | Functions of RANKL/RANK/OPG in bone modeling and remodeling |
| Q36532578 | Future anti-catabolic therapeutic targets in bone disease |
| Q33721928 | Generation of lymph node-fat pad chimeras for the study of lymph node stromal cell origin |
| Q46614093 | Genes Critical for Developing Periodontitis: Lessons from Mouse Models |
| Q38019409 | Genes associate with abnormal bone cell activity in bone metastasis |
| Q58326890 | Genetic control of skeletal development |
| Q30168513 | Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival |
| Q30534404 | Genetic polymorphism of the OPG gene associated with breast cancer |
| Q36568293 | Genome-wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A, and Identification of ZBTB10 and Three Distinct HLA Associations |
| Q34982927 | Glycosaminoglycans modulate RANKL-induced osteoclastogenesis |
| Q48368263 | Granzyme A Contributes to Inflammatory Arthritis in Mice Through Stimulation of Osteoclastogenesis. |
| Q54452122 | HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors. |
| Q80398194 | Hematological defects in the oc/oc mouse, a model of infantile malignant osteopetrosis |
| Q64264445 | Hematopoietic or Osteoclast-Specific Deletion of Syk Leads to Increased Bone Mass in Experimental Mice |
| Q85563000 | High bone mass in the STR/ort mouse results from increased bone formation and impaired bone resorption and is associated with extramedullary hematopoiesis |
| Q38944254 | High glucose inhibits receptor activator of nuclear factor‑κB ligand-induced osteoclast differentiation via downregulation of v‑ATPase V0 subunit d2 and dendritic cell‑specific transmembrane protein |
| Q37463716 | High- and low-dose OPG-Fc cause osteopetrosis-like changes in infant mice. |
| Q40696407 | Histamine stimulates production of osteoclast differentiation factor/receptor activator of nuclear factor-kappaB ligand by osteoblasts |
| Q36572545 | Hodgkin's lymphoma: molecular targets and novel treatment strategies |
| Q34137037 | How B cells influence bone biology in health and disease |
| Q35115283 | Human mesenchymal stem cells as delivery of osteoprotegerin gene: homing and therapeutic effect for osteosarcoma |
| Q24310432 | Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations |
| Q47310464 | Hyperbaric oxygen therapy modulates serum OPG/RANKL in femoral head necrosis patients. |
| Q36292663 | IKK{beta} as a target for treatment of inflammation induced bone loss |
| Q36403428 | IL-1 receptor-associated kinase M is a central regulator of osteoclast differentiation and activation |
| Q41137165 | IL-10 critically modulates B cell responsiveness in Rankl-/- mice. |
| Q51027178 | IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL |
| Q46372900 | IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. |
| Q84033281 | Identification and characterization of anti-osteoclastogenic peptides derived from the cytoplasmic tail of receptor activator of nuclear factor kappa B |
| Q33225474 | Identification of an alternatively spliced variant of Ca2+-promoted Ras inactivator as a possible regulator of RANKL shedding |
| Q36924500 | Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration |
| Q38134126 | Immune cells and bone: coupling goes both ways. |
| Q37701076 | Immune mediators in the tumor microenvironment of prostate cancer |
| Q39908266 | Impaired micro-RNA pathways diminish osteoclast differentiation and function |
| Q38183262 | Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib. |
| Q35378487 | Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-kappaB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclasts |
| Q37720404 | Individual and combining effects of anti-RANKL monoclonal antibody and teriparatide in ovariectomized mice |
| Q40655044 | Induction of Osteoclast Differentiation by Runx2 through Receptor Activator of Nuclear Factor-κB Ligand (RANKL) and Osteoprotegerin Regulation and Partial Rescue of Osteoclastogenesis in Runx2–/– Mice by RANKL Transgene |
| Q38960255 | Induction of the alternative NF-κB pathway by lymphotoxin αβ (LTαβ) relies on internalization of LTβ receptor |
| Q35643989 | Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? |
| Q36518539 | Inflammation-induced bone remodeling in periodontal disease and the influence of post-menopausal osteoporosis |
| Q36497982 | Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function |
| Q37989394 | Inflammatory bone loss: pathogenesis and therapeutic intervention |
| Q57450690 | Infliximab attenuates inflammatory osteolysis in a model of periodontitis in Wistar rats |
| Q98613272 | Inhibition of Axin1 in osteoblast precursor cells leads to defects in postnatal bone growth through suppressing osteoclast formation |
| Q28571624 | Inhibition of osteoclastogenesis by the secretion of osteoprotegerin in vitro by rat dental follicle cells and its implications for tooth eruption |
| Q38752770 | Interaction of Tumor Necrosis Factor Receptor-associated Factor 6 (TRAF6) and Vav3 in the Receptor Activator of Nuclear Factor κB (RANK) Signaling Complex Enhances Osteoclastogenesis. |
| Q36908519 | Interaction of bone morphogenetic proteins with cells of the osteoclast lineage: review of the existing evidence |
| Q37270187 | Interactions between immune and bone cells: new insights with many remaining questions |
| Q21092154 | Interleukin-32 promotes osteoclast differentiation but not osteoclast activation |
| Q36402985 | I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss |
| Q34424720 | Kruppel-like factor 4 expression in osteoblasts represses osteoblast-dependent osteoclast maturation |
| Q43782638 | Linkage of M-CSF signaling to Mitf, TFE3, and the osteoclast defect in Mitf(mi/mi) mice |
| Q35748002 | Linking hematopoiesis to endochondral skeletogenesis through analysis of mice transgenic for collagen X. |
| Q51364696 | Lipopolysaccharide increases IL-6 secretion via activation of the ERK1/2 signaling pathway to up-regulate RANKL gene expression in MLO-Y4 cells. |
| Q54614405 | Local gene transfer of OPG prevents joint damage and disease progression in collagen-induced arthritis. |
| Q50004069 | Locally Aggressive Connective Tissue Tumors. |
| Q36290311 | Lymphoid organogenesis in the intestine. |
| Q37573975 | Lymphoid tissue inducer cells: architects of CD4 immune responses in mice and men. |
| Q49896661 | Lymphoid tissue inducer-A divergent member of the ILC family. |
| Q38844780 | Macrophage heterogeneity in the context of rheumatoid arthritis. |
| Q64102130 | Mapping of Dynamic Transcriptome Changes Associated With Silica-Triggered Autoimmune Pathogenesis in the Lupus-Prone NZBWF1 Mouse |
| Q42234109 | Marginal reticular cells: a stromal subset directly descended from the lymphoid tissue organizer. |
| Q28247746 | Matrix-embedded cells control osteoclast formation |
| Q52578848 | Mechanisms involved in normal and pathological osteoclastogenesis. |
| Q37106639 | Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets |
| Q47756922 | Mechanisms of bone destruction in multiple myeloma |
| Q99234123 | Mechanisms of bone development and repair |
| Q41922030 | Mediators of inflammation-induced bone damage in arthritis and their control by herbal products |
| Q40663935 | Membrane rafts play a crucial role in receptor activator of nuclear factor kappaB signaling and osteoclast function |
| Q60924644 | Mepazine Inhibits RANK-Induced Osteoclastogenesis Independent of Its MALT1 Inhibitory Function |
| Q34627979 | Methanol Extract of Croton Pycnanthus Benth. Inhibits Osteoclast Differentiation by Suppressing the MAPK and NF-κB Signaling Pathways |
| Q34496406 | Microenvironmental niches in the bone marrow required for B-cell development |
| Q40756889 | Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling |
| Q90671325 | Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer |
| Q34298341 | Modulating the intestinal immune system: the role of lymphotoxin and GALT organs |
| Q47105411 | Molecular Pathogenesis and Diagnostic Imaging of Metastatic Jaw Tumors |
| Q39592784 | Molecular and functional characteristics of heart-valve interstitial cells |
| Q34106530 | Molecular control of bone remodeling and osteoporosis |
| Q37169549 | Molecular mechanism of the bifunctional role of lipopolysaccharide in osteoclastogenesis |
| Q35664993 | Molecular mechanisms of the biphasic effects of interferon-γ on osteoclastogenesis |
| Q38074961 | Molecular mechanisms of triggering, amplifying and targeting RANK signaling in osteoclasts |
| Q35157702 | Molecular mechanisms underlying osteoclast formation and activation |
| Q38155649 | Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor |
| Q37733733 | Monogenic Autoinflammatory Diseases with Mendelian Inheritance: Genes, Mutations, and Genotype/Phenotype Correlations. |
| Q49589290 | Morphological characteristics of osteopetrosis |
| Q33944879 | Mouse genetics have uncovered new paradigms in bone biology |
| Q38155200 | Multifunctional properties of RANKL/RANK in cell differentiation, proliferation and metastasis |
| Q42795870 | Multimerization of the receptor activator of nuclear factor-kappaB ligand (RANKL) isoforms and regulation of osteoclastogenesis |
| Q33944735 | Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression |
| Q35953074 | Mutation in Osteoactivin Promotes Receptor Activator of NFκB Ligand (RANKL)-mediated Osteoclast Differentiation and Survival but Inhibits Osteoclast Function |
| Q28271031 | NF-kappaB and the immune response |
| Q37363042 | NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism |
| Q37653034 | NF-κB RelB negatively regulates osteoblast differentiation and bone formation |
| Q35348282 | NF-κB in immunobiology. |
| Q57675122 | NF-κB p50 and p52 Regulate Receptor Activator of NF-κB Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1 |
| Q34059280 | Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis |
| Q37643579 | Neonatal High Bone Mass With First Mutation of the NF-κB Complex: Heterozygous De Novo Missense (p.Asp512Ser) RELA (Rela/p65). |
| Q37127171 | Neural progenitor cell-mediated delivery of osteoprotegerin limits disease progression in a preclinical model of neuroblastoma bone metastasis |
| Q64235920 | New Insights for RANKL as a Proinflammatory Modulator in Modeled Inflammatory Arthritis |
| Q37748586 | New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis. |
| Q61814977 | Ninjurin1 positively regulates osteoclast development by enhancing the survival of prefusion osteoclasts |
| Q38636476 | Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases |
| Q37948121 | Non-canonical NF-κB signaling activation and regulation: principles and perspectives |
| Q28590415 | Notch signaling in osteocytes differentially regulates cancellous and cortical bone remodeling |
| Q36830310 | Novel osteoclast signaling mechanisms. |
| Q38205860 | Novel techniques in the development of osteoporosis drug therapy: the osteoclast ruffled-border vacuolar H(+)-ATPase as an emerging target |
| Q35036364 | Nuclear export of the NF-κB inhibitor IκBα is required for proper B cell and secondary lymphoid tissue formation. |
| Q36938511 | Oral mucosal dendritic cells and periodontitis: many sides of the same coin with new twists |
| Q36209682 | Organizing a mucosal defense |
| Q35096187 | Organogenesis of lymphoid tissues |
| Q35216947 | Organogenesis of peripheral lymphoid organs. |
| Q90631432 | Origins of Alterations to Rankl Null Mutant Mouse Dental Root Development |
| Q36542861 | Osteoblast lineage-specific effects of notch activation in the skeleton |
| Q39190775 | Osteoblast-osteoclast interactions |
| Q35348955 | Osteoclast activity modulates B-cell development in the bone marrow |
| Q29547556 | Osteoclast differentiation and activation |
| Q24605866 | Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer |
| Q36402845 | Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis |
| Q28593804 | Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha |
| Q36568536 | Osteoclast fusion and regulation by RANKL-dependent and independent factors |
| Q28507297 | Osteoclast inhibitory lectin, a family of new osteoclast inhibitors |
| Q51079985 | Osteoclast lineage commitment of bone marrow precursors through expression of membrane-bound TRANCE. |
| Q36324916 | Osteoclast precursors, RANKL/RANK, and immunology |
| Q35598821 | Osteoclast progenitors reside in the peroxisome proliferator-activated receptor γ-expressing bone marrow cell population |
| Q42679472 | Osteoclast regulation of osteoblasts via RANK‑RANKL reverse signal transduction in vitro |
| Q90224356 | Osteoclast-Like Cells in Aneurysmal Disease Exhibit an Enhanced Proteolytic Phenotype |
| Q36580426 | Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation |
| Q37118763 | Osteoclasts - the innate immune cells of the bone |
| Q37489600 | Osteoclasts and the immune system |
| Q35070894 | Osteoclasts are dispensable for hematopoietic progenitor mobilization by granulocyte colony-stimulating factor in mice |
| Q42831459 | Osteoclasts are not crucial for hematopoietic stem cell maintenance in adult mice |
| Q35826041 | Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow |
| Q35755039 | Osteoclasts: New Insights |
| Q88248494 | Osteoimmunology |
| Q37626412 | Osteoimmunology and the effects of the immune system on bone |
| Q26828486 | Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclasts |
| Q89820667 | Osteoimmunology: A Current Update of the Interplay Between Bone and the Immune System |
| Q27008993 | Osteoimmunology: Major and Costimulatory Pathway Expression Associated with Chronic Inflammatory Induced Bone Loss |
| Q47944184 | Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems. |
| Q36942525 | Osteoimmunology: a view from the bone |
| Q37544448 | Osteoimmunology: crosstalk between the immune and bone systems |
| Q24655113 | Osteoimmunology: interactions of the bone and immune system |
| Q38960189 | Osteoimmunology: memorandum for rheumatologists. |
| Q34371936 | Osteopenia and osteoporosis in gastrointestinal diseases: diagnosis and treatment |
| Q34560598 | Osteoprotegerin |
| Q42502915 | Osteoprotegerin and rank ligand expression in prostate cancer |
| Q36150705 | Osteoprotegerin deficiency results in disruption of posterofrontal suture closure in mice: implications in nonsyndromic craniosynostosis |
| Q40553401 | Osteoprotegerin in human milk: a potential role in the regulation of bone metabolism and immune development |
| Q34079327 | Osteoprotegerin ligand: a regulator of immune responses and bone physiology. |
| Q36029217 | Paget disease of bone |
| Q35568480 | Panostotic expansile bone disease with massive jaw tumor formation and a novel mutation in the signal peptide of RANK. |
| Q73197583 | Participation of protein kinase C beta in osteoclast differentiation and function |
| Q37187646 | Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments. |
| Q37810077 | Pathogenesis and management of myeloma bone disease |
| Q34637331 | Pathogenesis of bone lesions in rheumatoid arthritis |
| Q46224909 | Pathogenesis of myeloma bone disease |
| Q53625757 | Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG). |
| Q52940259 | Periosteal hyperostosis (exostosis) in DBA/1 male mice. |
| Q54379479 | Phosphatidylserine-containing liposomes suppress inflammatory bone loss by ameliorating the cytokine imbalance provoked by infiltrated macrophages. |
| Q36944827 | Phospholipase Cgamma2 mediates RANKL-stimulated lymph node organogenesis and osteoclastogenesis |
| Q34369482 | Physiological functions of osteoblast lineage and T cell-derived RANKL in bone homeostasis |
| Q37810596 | Physiology and pathophysiology of the RANKL/RANK system |
| Q43984049 | Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanism |
| Q34344623 | Podosome organization drives osteoclast-mediated bone resorption. |
| Q35617594 | Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis |
| Q51644067 | Possible mechanisms of the crosstalk between Langerhans cells and regulatory T cells in extramammary Paget disease by receptor activator of nuclear factor kappa B (RANK) ligand/RANK pathways. |
| Q41825243 | Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death. |
| Q34321877 | Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. |
| Q37249108 | Progesterone receptor and Stat5 signaling cross talk through RANKL in mammary epithelial cells |
| Q35002815 | Progranulin and a five transmembrane domain-containing receptor-like gene are the key components in receptor activator of nuclear factor κB (RANK)-dependent formation of multinucleated osteoclasts |
| Q38878942 | Proteomic approaches to study osteoclast biology |
| Q45899252 | Pulsed electromagnetic field stimulates osteoprotegerin and reduces RANKL expression in ovariectomized rats. |
| Q28302165 | Pulsed electromagnetic fields improve bone microstructure and strength in ovariectomized rats through a Wnt/Lrp5/β-catenin signaling-associated mechanism |
| Q85661114 | Pulsed electromagnetic fields inhibit bone loss in streptozotocin-induced diabetic rats |
| Q38691526 | RANK as a therapeutic target in cancer. |
| Q37108966 | RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism |
| Q36600255 | RANK ligand inhibition with denosumab for the management of osteoporosis |
| Q28294501 | RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis |
| Q35641868 | RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini |
| Q33825207 | RANK receptor oligomerisation in the regulation of NFκB signalling |
| Q41868543 | RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla |
| Q34209272 | RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis |
| Q37199218 | RANK, RANKL and osteoprotegerin in bone biology and disease. |
| Q35053943 | RANK-Fc: a therapeutic antagonist for RANK-L in myeloma |
| Q26747442 | RANK-RANKL signalling in cancer |
| Q35837418 | RANK-dependent autosomal recessive osteopetrosis: characterization of five new cases with novel mutations |
| Q41107411 | RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. |
| Q27674275 | RANKL Employs Distinct Binding Modes to Engage RANK and the Osteoprotegerin Decoy Receptor |
| Q89666841 | RANKL biology: bone metabolism, the immune system, and beyond |
| Q37730637 | RANKL coordinates multiple osteoclastogenic pathways by regulating expression of ubiquitin ligase RNF146. |
| Q36898545 | RANKL cytokine: from pioneer of the osteoimmunology era to cure for a rare disease |
| Q37532561 | RANKL inhibition for the management of patients with benign metabolic bone disorders. |
| Q37865171 | RANKL inhibition: a promising novel strategy for breast cancer treatment. |
| Q59806646 | RANKL signaling in bone marrow mesenchymal stem cells negatively regulates osteoblastic bone formation |
| Q36246148 | RANKL synthesized by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritis |
| Q37241264 | RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases |
| Q36412789 | RANKL-RANK interaction in immune regulatory systems |
| Q52717305 | RANKL-mediated osteoclastogenic differentiation of macrophages in the abdominal aorta of angiotensin II-infused apolipoprotein E knockout mice. |
| Q38306944 | RANKL/OPG; Critical role in bone physiology. |
| Q37457304 | RANKL/RANK control Brca1 mutation-driven mammary tumors |
| Q28308042 | RANKL/RANK-beyond bones |
| Q60917149 | RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives |
| Q28075004 | RANKL/RANK: from bone loss to the prevention of breast cancer |
| Q37730794 | RIP140 in monocytes/macrophages regulates osteoclast differentiation and bone homeostasis |
| Q35800463 | RNA therapeutics targeting osteoclast-mediated excessive bone resorption |
| Q58776864 | Rab GTPases in Osteoclastic Endomembrane Systems |
| Q39645396 | Rab27a and Rab27b are involved in stimulation-dependent RANKL release from secretory lysosomes in osteoblastic cells |
| Q34611297 | Reaching a genetic and molecular understanding of skeletal development |
| Q50215136 | Recent advances in osteoclast biology. |
| Q28740575 | Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients |
| Q34358320 | Receptor activator of NF-kappaB and podocytes: towards a function of a novel receptor-ligand pair in the survival response of podocyte injury |
| Q24537518 | Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6 |
| Q53655018 | Receptor activator of NF-κB ligand arrests bone growth and promotes cortical bone resorption in growing rats |
| Q73904964 | Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia |
| Q36860987 | Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. |
| Q34086847 | Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases |
| Q27021109 | Regulation of NFATc1 in Osteoclast Differentiation |
| Q38884628 | Regulation of Osteoblast Migration Involving Receptor Activator of Nuclear Factor-kappa B (RANK) Signaling. |
| Q38679162 | Regulation of RANKL-induced osteoclastogenesis by RING finger protein RNF114. |
| Q37884121 | Regulation of bone by the adaptive immune system in arthritis |
| Q34250588 | Regulation of bone cell development and function: implication for renal osteodystrophy. |
| Q28593319 | Regulation of osteoclast differentiation |
| Q26996000 | Regulation of osteoclasts by membrane-derived lipid mediators |
| Q36368551 | Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE |
| Q40796459 | Regulation of receptor activator of NF-kappaB ligand-induced tartrate-resistant acid phosphatase gene expression by PU.1-interacting protein/interferon regulatory factor-4. Synergism with microphthalmia transcription factor |
| Q35216951 | Regulation of secondary lymphoid organ development by the nuclear factor-kappaB signal transduction pathway |
| Q38183261 | Regulatory mechanisms of RANKL presentation to osteoclast precursors |
| Q34728971 | Regulatory mechanisms of osteoblast and osteoclast differentiation |
| Q37635761 | RelB-induced expression of Cot, an MAP3K family member, rescues RANKL-induced osteoclastogenesis in alymphoplasia mice by promoting NF-κB2 processing by IKKα. |
| Q36369876 | Requirement for the NF-kappaB family member RelA in the development of secondary lymphoid organs |
| Q35174052 | Requirement of the inducible nitric oxide synthase pathway for IL-1-induced osteoclastic bone resorption |
| Q33719241 | Retinoic acid increases proliferation of human osteoclast progenitors and inhibits RANKL-stimulated osteoclast differentiation by suppressing RANK |
| Q24642725 | Retinoid-related orphan receptor gamma (RORgamma) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis |
| Q36272906 | Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease |
| Q33926132 | Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors |
| Q28594052 | Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice |
| Q37118782 | Review: Immune cells and mediators of inflammatory arthritis |
| Q36324975 | Rheumatic diseases: the effects of inflammation on bone |
| Q33744585 | Role of RANK and Akt1 activation in human osteosarcoma progression: A clinicopathological study |
| Q34963016 | Role of RANKL and RANK in bone loss and arthritis. |
| Q28283972 | Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system |
| Q35037300 | Role of T and NK cells and IL7/IL7r interactions during neonatal maturation of lymph nodes |
| Q41457800 | Role of Tertiary Lymphoid Structures (TLS) in Anti-Tumor Immunity: Potential Tumor-Induced Cytokines/Chemokines that Regulate TLS Formation in Epithelial-Derived Cancers |
| Q37571986 | Role of denosumab in breast cancer |
| Q36324929 | Role of nuclear factor-kappaB in the immune system and bone |
| Q37241261 | Role of osteoclasts in regulating hematopoietic stem and progenitor cells |
| Q36684209 | Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification. |
| Q34886943 | Role of periodontal pathogenic bacteria in RANKL-mediated bone destruction in periodontal disease |
| Q39647821 | Role of zeta PKC in B-cell signaling and function |
| Q36177501 | Roles for NF-kappaB and c-Fos in osteoclasts |
| Q38056632 | Roles of Wnt signals in bone resorption during physiological and pathological states. |
| Q60489259 | Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy |
| Q35949809 | Runx2 regulates endochondral ossification through control of chondrocyte proliferation and differentiation |
| Q35689812 | Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis |
| Q37397090 | Secondary lymphoid organs: responding to genetic and environmental cues in ontogeny and the immune response |
| Q39714931 | Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis |
| Q47446256 | Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo |
| Q42052780 | Selective local delivery of RANK siRNA to bone phagocytes using bone augmentation biomaterials |
| Q34090842 | Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis. |
| Q37667201 | Serum osteoprotegerin concentration with strontium ranelate treatment for postmenopausal osteoporosis: an open, prospective study |
| Q92602305 | Sex-determining region Y (SRY) attributes to gender differences in RANKL expression and incidence of osteoporosis |
| Q51562477 | Sialoglycoproteins prepared from the eggs of Carassius auratus prevent bone loss by inhibiting the NF-κB pathway in ovariectomized rats. |
| Q35126799 | Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts |
| Q26766637 | Signaling Pathways in Osteoclast Differentiation |
| Q36082866 | Signaling networks that control the lineage commitment and differentiation of bone cells |
| Q35553533 | Signalling in osteoclasts and the role of Fos/AP1 proteins |
| Q83425416 | Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis |
| Q38009712 | Skeletal and extraskeletal actions of denosumab. |
| Q48405777 | Spatial (Tbata) expression in mature medullary thymic epithelial cells |
| Q34182834 | Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data |
| Q38736047 | Stem cells applications in bone and tooth repair and regeneration: New insights, tools, and hopes |
| Q36636031 | Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor-κB ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitory activity |
| Q34166675 | Strength of TRAF6 signalling determines osteoclastogenesis |
| Q41841106 | Stroma cell priming in enteric lymphoid organ morphogenesis |
| Q58710472 | Systemic Activation of Activin A Signaling Causes Chronic Kidney Disease-Mineral Bone Disorder |
| Q27311542 | T cells induce pre-metastatic osteolytic disease and help bone metastases establishment in a mouse model of metastatic breast cancer |
| Q36560045 | TAK1 is essential for osteoclast differentiation and is an important modulator of cell death by apoptosis and necroptosis |
| Q30743828 | TNF ligands and receptors in autoimmunity: an update |
| Q34542205 | TNF ligands and receptors--a matter of life and death |
| Q38042619 | TNF receptor family signaling in the development and functions of medullary thymic epithelial cells |
| Q34690481 | TNFα-dependent development of lymphoid tissue in the absence of RORγt⁺ lymphoid tissue inducer cells |
| Q28587065 | TRAF4 deficiency leads to tracheal malformation with resulting alterations in air flow to the lungs |
| Q36058895 | Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility. |
| Q26752785 | Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer |
| Q37293344 | Targeting NF-kappaB: a promising molecular therapy in inflammatory arthritis. |
| Q99594459 | Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study |
| Q26849690 | Targeting RANKL in metastasis |
| Q36322534 | Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia |
| Q98771227 | Targeting the RANKL/RANK/OPG Axis for Cancer Therapy |
| Q38810926 | Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers |
| Q33794960 | The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. |
| Q58109102 | The Cellular Biology of Fracture Healing |
| Q36649905 | The Dmp1-SOST Transgene Interacts With and Downregulates the Dmp1-Cre Transgene and the Rosa(Notch) Allele |
| Q37485598 | The First Scube3 Mutant Mouse Line with Pleiotropic Phenotypic Alterations. |
| Q89314569 | The Osteoclast in Bone Metastasis: Player and Target |
| Q35603143 | The PCa Tumor Microenvironment |
| Q51800938 | The Potential of Probiotics as a Therapy for Osteoporosis. |
| Q64102143 | The RANKL-RANK Axis: A Bone to Thymus Round Trip |
| Q34090732 | The ROR nuclear orphan receptor subfamily: critical regulators of multiple biological processes |
| Q91868580 | The Role of Endothelial Cells and TNF-Receptor Superfamily Members in Lymphoid Organogenesis and Function During Health and Inflammation |
| Q92050583 | The Role of NF-κB in Physiological Bone Development and Inflammatory Bone Diseases: Is NF-κB Inhibition "Killing Two Birds with One Stone"? |
| Q38938475 | The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease |
| Q28389140 | The T-cell oncogene Tal2 Is a Target of PU.1 and upregulated during osteoclastogenesis |
| Q28203717 | The TNF and TNF receptor superfamilies: integrating mammalian biology |
| Q36969029 | The TNF receptor and Ig superfamily members form an integrated signaling circuit controlling dendritic cell homeostasis |
| Q88954027 | The Tumor Necrosis Factor Superfamily Member RANKL Suppresses Effector Cytokine Production in Group 3 Innate Lymphoid Cells |
| Q45222983 | The V-ATPase a3 subunit mutation R740S is dominant negative and results in osteopetrosis in mice |
| Q28508398 | The association of Notch2 and NF-kappaB accelerates RANKL-induced osteoclastogenesis |
| Q35868802 | The biology of progesterone receptor in the normal mammary gland and in breast cancer |
| Q38367239 | The contribution of NF-κB signalling to immune regulation and tolerance |
| Q38029394 | The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction |
| Q35216957 | The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity |
| Q24683018 | The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games |
| Q50988892 | The many ways of osteoclast activation. |
| Q50651156 | The mineral dissolution function of osteoclasts is dispensable for hypertrophic cartilage degradation during long bone development and growth. |
| Q37423147 | The molecular mechanism behind bone remodelling: a review |
| Q42611864 | The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts |
| Q28142247 | The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development |
| Q38763612 | The osteoimmunology of alveolar bone loss |
| Q28582633 | The osteopetrotic mutation toothless (tl) is a loss-of-function frameshift mutation in the rat Csf1 gene: Evidence of a crucial role for CSF-1 in osteoclastogenesis and endochondral ossification |
| Q42905527 | The paired-box homeodomain transcription factor Pax6 binds to the upstream region of the TRAP gene promoter and suppresses receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation. |
| Q37520235 | The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases. |
| Q36422055 | The protocol for the isolation and cryopreservation of osteoclast precursors from mouse bone marrow and spleen |
| Q35831159 | The regulation of osteoclast differentiation by Wnt signals |
| Q35005856 | The role of CD45+CD4+CD3- cells in lymphoid organ development |
| Q37598359 | The role of T helper type 17 cells in inflammatory arthritis |
| Q24519770 | The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models |
| Q24805207 | The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. |
| Q90269012 | The role of bone cells in immune regulation during the course of infection |
| Q24797889 | The role of osteoprotegerin in arthritis |
| Q36324969 | The role of the immune system in the pathophysiology of osteoporosis |
| Q36333478 | The role of the immune system in the physiopathology of osteoporosis |
| Q28206376 | The role of the nuclear hormone receptor RORγt in the development of lymph nodes and Peyer's patches |
| Q35083231 | The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcification |
| Q26799134 | Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications |
| Q57243517 | Thirty-eight-negative kinase 1 (TNK1) facilitates TNFα-induced apoptosis by blocking NF-κB activation |
| Q36976545 | Toward improved phosphorus efficiency in monogastrics-interplay of serum, minerals, bone, and immune system after divergent dietary phosphorus supply in swine |
| Q38290706 | Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B. |
| Q38260633 | Translational biology of osteosarcoma |
| Q33713146 | Transplantation of mesenchymal stem cells overexpressing RANK-Fc or CXCR4 prevents bone loss in ovariectomized mice |
| Q35453039 | Treatment of immobilization-related hypercalcaemia with denosumab |
| Q36902828 | Treatment strategies for bone disease |
| Q36187103 | Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab |
| Q36829147 | Trophic macrophages in development and disease |
| Q38530619 | Tumor necrosis factor receptor- associated factor 6 (TRAF6) regulation of development, function, and homeostasis of the immune system |
| Q28592573 | Tumor necrosis factor receptor-associated factor 6 (TRAF6) deficiency results in exencephaly and is required for apoptosis within the developing CNS |
| Q73853199 | Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture |
| Q34734335 | Tumor necrosis factor-α signaling in macrophages. |
| Q36380499 | Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity |
| Q35194008 | Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling |
| Q28511182 | Tyrosine kinase receptor RET is a key regulator of Peyer's patch organogenesis |
| Q42139802 | Ubiquitin E3 Ligase LNX2 is Critical for Osteoclastogenesis In Vitro by Regulating M-CSF/RANKL Signaling and Notch2. |
| Q33775139 | Up-Regulation of RANK Expression via ERK1/2 by Insulin Contributes to the Enhancement of Osteoclast Differentiation |
| Q38414568 | Update on genetics and pathogenesis of autoinflammatory diseases: the last 2 years |
| Q64102242 | Updates on Osteoimmunology: What's New on the Cross-Talk Between Bone and Immune System |
| Q81673001 | Upregulation of receptor activator of nuclear factor-kappaB ligand expression in the thymic subcapsular, paraseptal, perivascular, and medullary epithelial cells during thymus regeneration |
| Q34590536 | Use of genetically engineered mice in drug discovery and development: wielding Occam's razor to prune the product portfolio |
| Q90294419 | Various roles of heme oxygenase-1 in response of bone marrow macrophages to RANKL and in the early stage of osteoclastogenesis |
| Q44534331 | Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand |
| Q39908618 | Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production |
| Q28204249 | X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling |
| Q64950655 | XRK3F2 Inhibition of p62-ZZ Domain Signaling Rescues Myeloma-Induced GFI1-Driven Epigenetic Repression of the Runx2 Gene in Pre-osteoblasts to Overcome Differentiation Suppression. |
| Q82078374 | [Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)] |
| Q33912421 | siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption |